z-logo
open-access-imgOpen Access
Stanowisko polskich ekspertów dotyczące zastosowania leku brentuksymab vedotin w leczeniu chorych na pierwotne chłoniaki skóry CD30+
Author(s) -
Małgorzata SokołowskaWojdyło,
Jan Walewski,
Wiesław Wiktor Jędrzejczak,
Tadeusz Robak,
Monika ProchorecSobieszek,
Jan Maciej Zaucha,
Alina JankowskaKonsur,
Monika Słowińska,
Ewa Chmielowska,
Lidia Rudnicka,
Sebastian Giebel
Publication year - 2018
Publication title -
hematologia
Language(s) - Polish
Resource type - Journals
SCImago Journal Rank - 0.136
H-Index - 5
eISSN - 2081-3287
pISSN - 2081-0768
DOI - 10.5603/hem.2018.0015
Subject(s) - brentuximab vedotin , lymphomatoid papulosis , bexarotene , mycosis fungoides , medicine , dermatology , cd30 , oncology , lymphoma , chemistry , biochemistry , nuclear receptor , transcription factor , gene

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here